News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium Pharmaceuticals, Inc. (South San Francisco, California) (MLNM) Submits Two Supplemental NDAs to FDA for VELCADE


4/26/2011 8:52:43 AM

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADEĀ® (bortezomib) for Injection to the U.S. Food and Drug Administration (FDA). The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES